Miller-Fisher syndrome in a patient with rheumatoid arthritis treated with adalimumab.

Autoria(s): Kurmann P.T.; Van Linthoudt D.; So A.K.
Data(s)

2009
Resumo

Adalimumab is a frequently prescribed TNFalpha inhibitor for treatment of rheumatoid arthritis. We report on a patient who probably developed a Miller-Fisher syndrome after the second injection of adalimumab.
Identificador

http://serval.unil.ch/?id=serval:BIB_90329B237134

isbn:1434-9949[electronic]

pmid:18818868

doi:10.1007/s10067-008-1017-7

isiid:000261185900016
Idioma(s)

en
Fonte

Clinical Rheumatology, vol. 28, no. 1, pp. 93-94
Palavras-Chave #Aged; Amines/therapeutic use; Antibodies, Monoclonal/adverse effects; Antirheumatic Agents/adverse effects; Arthritis, Rheumatoid/drug therapy; Azathioprine/therapeutic use; Cyclohexanecarboxylic Acids/therapeutic use; Dose-Response Relationship, Drug; Female; Glucocorticoids/therapeutic use; Humans; Miller Fisher Syndrome/etiology; Miller Fisher Syndrome/physiopathology; Treatment Outcome; Tumor Necrosis Factor-alpha/antagonists & inhibitors; gamma-Aminobutyric Acid/therapeutic use
Tipo

info:eu-repo/semantics/article

article
Acesso ao item digital